Selective pharmacological inhibition of epac1 for the treatment of idiopathic pulmonary fibrosis

The present invention relates to the treatment of idiopathic pulmonary fibrosis. Today, there is no cure for IPF. The inventors showed that EPAC1 inhibitors, in particular CE3F4 and AM-0001, represent a promising therapeutic strategy for treating patients with pulmonary fibrosis. The present invention thus relates to an EPAC1 inhibitor for use in the treatment and/or prevention of idiopathic pulmonary fibrosis.

Keywords: IPF, Pulmonary, Fibrosis, Idiopathic Pulmonary Fibrosis, Epac1, Respiratory diseases
Patent Application number: 19306645.3

Reference:

CHIM19384-T1

Business Developper
contact
Aymeric Empereur
Aymeric Empereur
Business Developer
Patent filling date: 2019-12-13

You might also be interested in